Ivermectin Tablets

Pioneers in the industry, we offer albendazole+ivermectin zbd plus, fenbendazole+ivermectin fendikind plus pet tablet and nirmatrelvir,ritonavir paxobrook kit from India.

Albendazole+Ivermectin ZBD PLUS

Request Callback

₹ 700 Get Latest Price

Product Brochure
Strength400 mg + 12 mg
Packaging Size1*10 Tablets
Packaging TypeStrip
BrandZBD PLUS
Manufacturerhealling pharma

Minimum order quantity: 10 Box

ZBD PLUS TABLET contains a combination of Albendazole and Ivermectin, which belongs to a group of medicines called Anthelmintics. It is used to treat parasitic and worm infestations. Parasitic worm infections are intestinal worm infections that are caused by the ingestion of contaminated food and water.

Fenbendazole+Ivermectin Fendikind Plus Pet Tablet

Request Callback

₹ 500 Get Latest Price

Product Brochure
Packaging Size1X1 Bolus
Packaging TypeBox
CompositionFenbendazole 3000 mg + Ivermectin 100 mg
Shelf Life24 months
Prescription/Non prescriptionNon prescription
Country of originMade in India

Minimum order quantity: 10 Box

Description: FENDIKIND-PLUS Bolus is a comprehensive deworming solution enriched with Fenbendazole and Ivermectin. Fenbendazole targets gastrointestinal nematodes, tapeworms, lice, and grubs, while Ivermectin effectively controls psoroptic mange.

Nirmatrelvir,Ritonavir Paxobrook Kit

Request Callback

₹ 7000 Get Latest Price

Product Brochure
Strength150 mg + 100 mg
Packaging Size1x30
CompositionNirmatrelvir,Ritonavi
brandPaxobrook Kit
Country of OriginMade in India

Minimum order quantity: 2 Box

What is Paxlovid used for? Paxlovid (nirmatrelvir and ritonavir) is commonly used to treat mild to moderate coronavirus disease 2019 (COVID-19) if you are at high risk of progression to severe COVID-19. Paxlovid may also be used for other conditions as determined by your healthcare provider.
X

Contact Us

Khushboo (CEO)
Shri Health Karts
304, Bharat Complex, Gurunanak Colony, Jaripatka, Nagpur
Mominpura, Nagpur - 440014, Maharashtra, India

Get Directions
Send Email
Share: